ALG2

Across TCGA pan-cancer cohorts, ALG2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ALG2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ALG2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ALG2 is over-expressed in tumor, although a few such as PDAC and LSCC show the opposite, repressed pattern.

HNSC, PDAC, and LSCC are the cancer types where ALG2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ALG2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	+0.304	<.001	11	view →
PDAC	Female	All	−1.086	<.001	8	view →
LSCC	All	All	−0.099	.001	4	view →
OV	All	All	−0.322	.029	2	view →
CCRCC	All	All	+0.066	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ALG2–HNSC

Open the HNSC breakdown →